Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Biotech Industry Analysis

UpdatedAug 22, 2026
DataAggregated Company Financials
Companies538
  • 7D6.9%
  • 3M22.2%
  • 1Y45.3%
  • YTD24.0%

In the last week, the Biotech industry is up 6.9%, with Moderna leading the way, up 129%. In the last 12 months, the industry was up 45%. Looking forward, earnings are forecast to grow by 28% annually.

Industry Valuation and Performance

Has the U.S. Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sun, 23 Aug 2026US$1.6tUS$173.0b-US$20,602,463,962.4417.4x-75.4x9x
Tue, 21 Jul 2026US$1.4tUS$169.2b-US$12,116,867,863.0017x-115.3x8.3x
Thu, 18 Jun 2026US$1.3tUS$170.0b-US$12,153,726,792.8816.4x-106.1x7.6x
Sat, 16 May 2026US$1.3tUS$171.4b-US$12,310,644,857.9517.4x-106.5x7.7x
Mon, 13 Apr 2026US$1.3tUS$166.2b-US$11,968,946,358.8017.5x-107.7x7.8x
Wed, 11 Mar 2026US$1.3tUS$169.1b-US$15,388,798,482.8821.5x-86.5x7.9x
Fri, 06 Feb 2026US$1.3tUS$164.4b-US$14,752,166,736.3519.7x-86.5x7.8x
Sun, 04 Jan 2026US$1.2tUS$163.5b-US$15,345,571,210.7721.1x-79x7.4x
Tue, 02 Dec 2025US$1.2tUS$163.6b-US$16,204,397,732.2218.7x-77.1x7.6x
Thu, 30 Oct 2025US$1.2tUS$164.0b-US$17,953,607,163.7417.4x-65.9x7.2x
Sat, 27 Sep 2025US$1.1tUS$163.5b-US$18,316,421,423.9516.3x-58.1x6.5x
Mon, 25 Aug 2025US$1.1tUS$163.6b-US$18,584,724,159.6315.1x-57.8x6.6x
Wed, 23 Jul 2025US$961.0bUS$155.2b-US$23,253,955,254.0116.5x-41.3x6.2x
Fri, 20 Jun 2025US$929.9bUS$155.9b-US$23,930,083,012.0216.9x-38.9x6x
Sun, 18 May 2025US$895.3bUS$155.9b-US$24,392,718,921.6016.3x-36.7x5.7x
Tue, 15 Apr 2025US$740.5bUS$119.2b-US$36,459,397,381.9019.9x-20.3x6.2x
Thu, 13 Mar 2025US$834.6bUS$118.7b-US$37,659,545,163.6818.4x-22.2x7x
Sat, 08 Feb 2025US$857.1bUS$117.3b-US$30,948,989,158.0417.2x-27.7x7.3x
Mon, 06 Jan 2025US$980.2bUS$149.6b-US$26,354,792,434.1217x-37.2x6.6x
Wed, 04 Dec 2024US$1.0tUS$149.9b-US$26,584,927,055.4016.5x-39.1x6.9x
Fri, 01 Nov 2024US$1.1tUS$147.3b-US$30,454,139,694.2717.1x-34.7x7.2x
Sun, 29 Sep 2024US$893.6bUS$113.2b-US$36,006,680,210.7121.3x-24.8x7.9x
Tue, 27 Aug 2024US$909.0bUS$113.1b-US$35,851,266,005.4623.3x-25.4x8x
Thu, 25 Jul 2024US$1.2tUS$164.5b-US$28,090,976,401.9328.2x-43x7.3x
Sat, 22 Jun 2024US$1.1tUS$164.4b-US$27,943,646,272.0028.1x-41.1x7x
Mon, 20 May 2024US$1.1tUS$164.6b-US$26,835,738,666.6423.9x-42.8x7x
Wed, 17 Apr 2024US$1.1tUS$164.2b-US$23,402,696,044.0520.5x-46.3x6.6x
Fri, 15 Mar 2024US$1.2tUS$167.4b-US$22,100,849,384.5416.3x-54.1x7.1x
Sun, 11 Feb 2024US$1.2tUS$169.3b-US$26,263,046,791.8719.8x-44.2x6.9x
Tue, 09 Jan 2024US$1.4tUS$204.8b-US$22,499,844,981.0020.8x-63.1x6.9x
Thu, 07 Dec 2023US$1.3tUS$204.6b-US$22,056,080,007.0019.4x-58.1x6.3x
Sat, 04 Nov 2023US$1.2tUS$206.7b-US$20,531,174,316.0018.8x-60.4x6x
Mon, 02 Oct 2023US$1.3tUS$207.4b-US$13,122,605,528.0017.1x-95.8x6.1x
Wed, 30 Aug 2023US$1.3tUS$207.6b-US$12,432,896,963.0017.8x-103.8x6.2x
Price to Earnings Ratio

-103.8x


Total Market Cap: US$1.3tTotal Earnings: -US$12,432,896,963.00Total Revenue: US$207.6bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Biotech Industry Price to Earnings3Y Average -59.8x202420252026
Current Industry PE
  • Investors are optimistic on the American Biotechs industry, and appear confident in long term growth rates.
  • The 3-year average PS ratio of 7.0x is lower than the industry's current PS ratio of 8.8x.
Past Earnings Growth
  • The earnings for companies in the Biotechs industry have deteriorated over the last three years.
  • Revenues have also declined 5.9% per year.
  • This means overall sales from these companies are declining and losses are subsequently expanding as well.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market-1.53%
Healthcare4.15%
Biotech6.92%
Biotech6.92%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
MRNA ModernaUS$145.13129.2%
+US$32.7b		435.1%PS26x
ABBV AbbVieUS$264.966.2%
+US$27.4b		25.8%PE74.7x
AMGN AmgenUS$439.335.8%
+US$13.0b		49.6%PE27.2x
VRTX Vertex PharmaceuticalsUS$548.058.4%
+US$10.7b		38.7%PE31.5x
GILD Gilead SciencesUS$146.125.6%
+US$9.6b		27.3%PS5.9x

Latest News

BNTX
US$116.57
BioNTech
7D
25.2%
1Y
5.1%
ABBV
US$264.96
AbbVie
7D
6.2%
1Y
25.8%
MRNA
US$145.13
Moderna
7D
129.2%
1Y
435.1%
MIRM
US$96.31
Mirum Pharmaceuticals
7D
-4.3%
1Y
34.7%
Narrative Update • Aug 21

MIRM: PSC Regulatory Reset Will Reframe Long Term Earnings Outlook

Mirum Pharmaceuticals' analyst price targets have edged lower by single digits in recent weeks, with revisions such as $150 to $137, $146 to $137, $145 to $140, and $129 to $123, as analysts balance raised revenue guidance and a supportive base business against fresh regulatory uncertainty around the volixibat program in primary sclerosing cholangitis. Analyst Commentary Recent research on Mirum Pharmaceuticals points to a mixed but generally constructive tone, with bullish analysts stressing execution in the base business and pipeline potential, even as they factor in new regulatory questions around volixibat in primary sclerosing cholangitis.
NTRA
US$332.03
Natera
7D
7.1%
1Y
100.5%
Seeking Alpha • Aug 20

Natera: Even 30% Annual Growth Through 2030 Doesn't Support $310 Per Share

Summary Natera is rated Sell at ~$310, as the stock price bakes in highly optimistic growth and profitability assumptions. Q2 revenue grew 37.7% to $752.8M, driven by oncology test volume and improved reimbursement, but profitability remains elusive. Even with 30% annual revenue growth and 25% operating margins by 2030, fair value is estimated at $255 per share—well below current levels. Exceptional execution and regulatory wins support the business, but current valuation leaves little room for upside or error. Read the full article on Seeking Alpha
ONC
US$374.47
BeOne Medicines
7D
7.8%
1Y
19.4%
Narrative Update • Aug 20

ONC: Hematology Pipeline And Solid Tumor Catalysts Will Drive Future Upside

BeOne Medicines' analyst fair value estimate has shifted to $433.02 from $412.35, as analysts factor in higher price targets following recent beat and raise quarters, supported by progress across both solid tumor and hematology pipelines. Analyst Commentary Recent Street research on BeOne Medicines points to a generally constructive tone, with most firms adjusting price targets higher after the latest beat and raise quarter and pipeline updates.
AMGN
US$439.33
Amgen
7D
5.8%
1Y
49.6%
Narrative Update • Aug 20

AMGN: IRS And Regulatory Setbacks Will Restrain Pipeline Driven Repricing

Amgen's analyst fair value estimate has moved from about $252.61 to roughly $271.69, reflecting a series of higher Street price targets that analysts link to Q2 earnings strength, an updated revenue and margin outlook, and confidence in the company’s pipeline and recently launched products. Analyst Commentary Street research on Amgen after Q2 clusters around a clear message.
VRTX
US$548.05
Vertex Pharmaceuticals
7D
8.4%
1Y
38.7%
Narrative Update • Aug 19

VRTX: Kidney And Endocrine Expansion Will Drive Future Stock Upside

Vertex Pharmaceuticals' analyst fair value estimate has shifted to $672 from $641 as analysts factor in the higher Street price targets, the recent addition to BofA's US 1 List, and reduced competitive uncertainty around the cystic fibrosis franchise. Analyst Commentary Recent Street research around Vertex Pharmaceuticals points to a generally constructive tone on the stock.
GILD
US$146.12
Gilead Sciences
7D
5.6%
1Y
27.3%
RYTM
US$110.00
Rhythm Pharmaceuticals
7D
-4.7%
1Y
6.5%
TNGX
US$23.88
Tango Therapeutics
7D
-6.7%
1Y
246.1%
ERAS
US$17.63
Erasca
7D
-4.1%
1Y
1,001.9%
COAG
US$49.16
Hemab Therapeutics Holdings
7D
-10.5%
1Y
n/a
COGT
US$36.73
Cogent Biosciences
7D
-3.2%
1Y
203.1%
DNTH
US$111.10
Dianthus Therapeutics
7D
-4.2%
1Y
357.2%
JBIO
US$21.34
Jade Biosciences
7D
-13.6%
1Y
159.3%